Taehyeong Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taehyeong Lim has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Youngjoo Byun
College of Pharmacy Korea University Sejong Republic of Korea
4 shared publications - Hee-Deung Park
School of Civil, Environmental and Architectural Engineering, Korea University, Seoul 02841, South Korea; KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, South Korea
2 shared publications - Hongmok Kwon
College of Pharmacy, Korea University, 2511 Sejong-ro, Sejong 30019, Republic of Korea
2 shared publications - Hyunsoo Ha
College of Pharmacy, Korea University
2 shared publications Bernie Byeonghoon Park
College of Pharmacy, Korea University
1 shared publicationDonghak Kim
Department of Biological Sciences, Konkuk University
1 shared publication
Latest Publications
- Open Access
- 11 December 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (51) , 50281-50299
Developing Gingerol-Based Analogs against Pseudomonas aeruginosa Infections
Pseudomonas aeruginosa (P. aeruginosa), a Gram-negative opportunistic pathogen, produces virulent factors and forms biofilms through a quorum sensing (QS) mechanism. Modulating QS networks is considered an effective strategy for treating P. aeruginosa infections. Particularly, the rhl system, one of the QS networks, can be a potential target in treating patients with chronic infections. We previously discovered that gingerol acts as a RhlR antagonist of P. aeruginosa. Based on the chemical structure of gingerol, we have designed and synthesized gingerol derivatives by introducing various functional groups in the middle and tail regions. A comprehensive structure-activity relationship study showed that compound 5a substituted with phenyl group in the tail region was the most potent in various biological assessments, such as RhlR binding affinity, rhl gene expression, and virulence factor production of P. aeruginosa. Furthermore, compound 5a decreased the biofilm formation and pathogenicity of P. aeruginosa. Interestingly, compound 5a also influenced las system in addition to the rhl system. Taken together, compound 5a can be utilized as a potent compound for controlling P. aeruginosa infection.
- 11 December 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (51) , 50281-50299
Open AccessDeveloping Gingerol-Based Analogs against Pseudomonas aeruginosa Infections
Pseudomonas aeruginosa (P. aeruginosa), a Gram-negative opportunistic pathogen, produces virulent factors and forms biofilms through a quorum sensing (QS) mechanism. Modulating QS networks is considered an effective strategy for treating P. aeruginosa infections. Particularly, the rhl system, one of the QS networks, can be a potential target in treating patients with chronic infections. We previously discovered that gingerol acts as a RhlR antagonist of P. aeruginosa. Based on the chemical structure of gingerol, we have designed and synthesized gingerol derivatives by introducing various functional groups in the middle and tail regions. A comprehensive structure-activity relationship study showed that compound 5a substituted with phenyl group in the tail region was the most potent in various biological assessments, such as RhlR binding affinity, rhl gene expression, and virulence factor production of P. aeruginosa. Furthermore, compound 5a decreased the biofilm formation and pathogenicity of P. aeruginosa. Interestingly, compound 5a also influenced las system in addition to the rhl system. Taken together, compound 5a can be utilized as a potent compound for controlling P. aeruginosa infection.
- Open Access
- 19 February 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (2) , 274
Recent Advance in Small Molecules Targeting RhlR of Pseudomonas aeruginosa
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic gram-negative pathogen that can cause various infections, particularly in patients with compromised host defenses. P. aeruginosa forms biofilms and produces virulence factors through quorum sensing (QS) network, resulting in resistance to antibiotics. RhlI/RhlR, one of key QS systems in P. aeruginosa, is considered an attractive target for inhibiting biofilm formation and attenuating virulence factors. Several recent studies examined small molecules targeting the RhlI/RhlR system and their in vitro and in vivo biological activities. In this review, RhlR-targeted modulators, including agonists and antagonists, are discussed with particular focus on structure-activity relationship studies and outlook for next-generation anti-biofilm agents.
- 19 February 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (2) , 274
Open AccessRecent Advance in Small Molecules Targeting RhlR of Pseudomonas aeruginosa
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic gram-negative pathogen that can cause various infections, particularly in patients with compromised host defenses. P. aeruginosa forms biofilms and produces virulence factors through quorum sensing (QS) network, resulting in resistance to antibiotics. RhlI/RhlR, one of key QS systems in P. aeruginosa, is considered an attractive target for inhibiting biofilm formation and attenuating virulence factors. Several recent studies examined small molecules targeting the RhlI/RhlR system and their in vitro and in vivo biological activities. In this review, RhlR-targeted modulators, including agonists and antagonists, are discussed with particular focus on structure-activity relationship studies and outlook for next-generation anti-biofilm agents.
- Open Access
- 11 December 2021
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 37 (1) , 269-279
TNP and its analogs: Modulation of IP6K and CYP3A4 inhibition
Inositol hexakisphosphate kinase (IP6K) is an important mammalian enzyme involved in various biological processes such as insulin signalling and blood clotting. Recent analyses on drug metabolism and pharmacokinetic properties on TNP (N2-(m-trifluorobenzyl), N6-(p-nitrobenzyl)purine), a pan-IP6K inhibitor, have suggested that it may inhibit cytochrome P450 (CYP450) enzymes and induce unwanted drug-drug interactions in the liver. In this study, we confirmed that TNP inhibits CYP3A4 in type I binding mode more selectively than the other CYP450 isoforms. In an effort to find novel purine-based IP6K inhibitors with minimal CYP3A4 inhibition, we designed and synthesised 15 TNP analogs. Structure-activity relationship and biochemical studies, including ADP-Glo kinase assay and quantification of cell-based IP7 production, showed that compound 9 dramatically reduced CYP3A4 inhibition while retaining IP6K-inhibitory activity. Compound 9 can be a tool molecule for structural optimisation of purine-based IP6K inhibitors.
- 11 December 2021
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 37 (1) , 269-279
Open AccessTNP and its analogs: Modulation of IP6K and CYP3A4 inhibition
Inositol hexakisphosphate kinase (IP6K) is an important mammalian enzyme involved in various biological processes such as insulin signalling and blood clotting. Recent analyses on drug metabolism and pharmacokinetic properties on TNP (N2-(m-trifluorobenzyl), N6-(p-nitrobenzyl)purine), a pan-IP6K inhibitor, have suggested that it may inhibit cytochrome P450 (CYP450) enzymes and induce unwanted drug-drug interactions in the liver. In this study, we confirmed that TNP inhibits CYP3A4 in type I binding mode more selectively than the other CYP450 isoforms. In an effort to find novel purine-based IP6K inhibitors with minimal CYP3A4 inhibition, we designed and synthesised 15 TNP analogs. Structure-activity relationship and biochemical studies, including ADP-Glo kinase assay and quantification of cell-based IP7 production, showed that compound 9 dramatically reduced CYP3A4 inhibition while retaining IP6K-inhibitory activity. Compound 9 can be a tool molecule for structural optimisation of purine-based IP6K inhibitors.
- 16 April 2021
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 31 (6) , 525-547
Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer – a review of patent literature
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, is a potential target protein for the imaging and treatment of patients with prostate cancer because of its o...
- 16 April 2021
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 31 (6) , 525-547
Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer – a review of patent literature
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, is a potential target protein for the imaging and treatment of patients with prostate cancer because of its o...